Case report of recurrent spontaneous tumor lysis syndrome in a patient with esophageal cancer recovered via chemotherapy.
Chemotherapy
Esophageal cancer
Laboratory tumor lysis syndrome
Spontaneous tumor lysis syndrome
Tumor lysis syndrome
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
11
09
2021
accepted:
06
10
2021
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Tumor lysis syndrome (TLS) is a life-threatening oncological emergency. Only one TLS case has been reported in patients with esophageal cancer. We report the case of a 61-year-old man with recurrent spontaneous TLS caused by esophageal cancer. He was admitted to our hospital to investigate low back pain and dysphagia. Endoscopy and computed tomography revealed esophageal cancer with multiple liver and bone metastases. He was diagnosed with laboratory TLS based on high serum uric acid and phosphorus. After intravenous fluids and allopurinol were administrated, chemotherapy with 5-fluorouracil and cisplatin was started the next day. Although he transiently developed clinical TLS, it was resolved with conservative treatment. However, mild renal dysfunction was prolonged and cisplatin was reduced in the second course. As a consequence, recurrence of spontaous TLS (sTLS) was induced at the end of the course. In the third course, docetaxel was added to the regimen, and since then the patient have not develop sTLS. To the best of our knowledge, this is the first report regarding recurrent sTLS developed on the basis of solid tumors and was successfully controlled by chemotherapy. Although TLS complications are rare in esophageal cancer, early diagnosis and the adjustment of regimen resulted in stable chemotherapy.
Identifiants
pubmed: 35402131
doi: 10.1007/s13691-021-00514-x
pii: 514
pmc: PMC8938533
doi:
Types de publication
Case Reports
Langues
eng
Pagination
97-103Informations de copyright
© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors state that they have no conflict of interest (COI).
Références
J Clin Oncol. 2008 Jun 1;26(16):2767-78
pubmed: 18509186
Clin Biochem. 2008 Oct;41(14-15):1117-25
pubmed: 18619431
N Engl J Med. 2011 May 12;364(19):1844-54
pubmed: 21561350
Clin Case Rep. 2017 Nov 13;5(12):2121-2126
pubmed: 29225869
Mol Cancer Res. 2019 Jul;17(7):1459-1467
pubmed: 30988165
Clin Oncol (R Coll Radiol). 2006 Dec;18(10):773-80
pubmed: 17168213
Gan To Kagaku Ryoho. 2008 Nov;35(12):2030-2
pubmed: 19106513
Br J Haematol. 2010 May;149(4):578-86
pubmed: 20331465
J Gastrointest Cancer. 2019 Sep;50(3):668-673
pubmed: 29691710
J Nephrol. 2004 Jan-Feb;17(1):50-6
pubmed: 15151259